Clinical aspects of therapeutic substitution.

abstract：:As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin...

journal_title：PharmacoEconomics

authors： Carroll C,Tappenden P,Rafia R,Hamilton J,Chambers D,Clowes M,Durrington P,Qureshi N,Wierzbicki AS

更新日期：2016-11-16 00:00:00

abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

journal_title：PharmacoEconomics

authors： Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Assessing the societal perspective in economic evaluations of new interventions requires estimates of indirect non-medical costs caused by the disease. Different methods exist for measuring the labor input function as a surrogate for these costs. They rarely specify the effect of health on labor and who gain...

journal_title：PharmacoEconomics

authors： Standaert B,Sauboin C,Leclerc QJ,Connolly MP

更新日期：2020-11-25 00:00:00

abstract：:Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

journal_title：PharmacoEconomics

authors： Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

更新日期：2008-01-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：:Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component...

journal_title：PharmacoEconomics

authors： Chang K,Nash D

更新日期：1998-07-01 00:00:00

abstract：:The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements fo...

journal_title：PharmacoEconomics

authors： Oostenbrink JB,Koopmanschap MA,Rutten FF

更新日期：2002-01-01 00:00:00

abstract：:The progressive increase in the prevalence of obesity and aging in the population is resulting in increased healthcare and disability spending. The burden of obesity is particularly relevant in old age, due to accumulating co-morbidities and changes in body composition. Sarcopenic obesity, a mix of over- and under-nut...

journal_title：PharmacoEconomics

authors： Corica F,Bianchi G,Corsonello A,Mazzella N,Lattanzio F,Marchesini G

更新日期：2015-07-01 00:00:00

abstract：:This study evaluated the cost of sequential treatment with once-daily ofloxacin or twice-daily ciprofloxacin in 474 hospitalised patients in different countries. The patients were treated intravenously for at least 3 days, then orally for 7 to 10 days or for 3 days beyond the disappearance of infection-related symptom...

journal_title：PharmacoEconomics

authors： Salewski E,Bassaris HP,Calangu S,Kitzes R,Kosmidis J,Raz R,Kompan L

更新日期：1997-04-01 00:00:00

abstract：:Drug utilisation in term and preterm neonates (i.e. less than 28 days of age) has been investigated prospectively in 4 clinical studies during the past 10 years. 3880 neonates with a mean gestational age of 34.5 weeks (corresponding birthweight 2280g) were enrolled in these studies. An overview indicates a high prev...

journal_title：PharmacoEconomics

authors： Gortner L

更新日期：1993-12-01 00:00:00

abstract：AIM:To determine the economic impact (cost-benefit analysis) of childhood varicella vaccination, with the Oka/Merck varicella zoster virus vaccine live (Varivax) in Italy. METHODS:This analysis is based on an epidemiological model of varicella zoster virus (VZV) dynamics adapted to the Italian situation. Cost data (Eu...

journal_title：PharmacoEconomics

authors： Coudeville L,Brunot A,Giaquinto C,Lucioni C,Dervaux B

更新日期：2004-01-01 00:00:00

abstract：:The National Institute for Health and Care Excellence (NICE) invited GlaxoSmithKline, the manufacturer of dabrafenib, to submit evidence for the clinical and cost effectiveness of dabrafenib for the treatment of unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma in accordance with the Institute'...

journal_title：PharmacoEconomics

authors： Fleeman N,Bagust A,Beale S,Boland A,Dickson R,Dwan K,Richardson M,Dundar Y,Davis H,Banks L

更新日期：2015-09-01 00:00:00

abstract：:Community-acquired pneumonia (CAP) is a common diagnosis and care of CAP is responsible for significant healthcare expenditures, the majority of which are for patients who require hospitalisation. Studies have shown that significant variation exists among institutions with respect to antibacterial costs and length of ...

journal_title：PharmacoEconomics

authors： Brown PD

更新日期：2004-01-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...

journal_title：PharmacoEconomics

authors： Bermejo I,Ren S,Simpson E,Clowes M,Scott DL,Young A,Stevenson M

更新日期：2018-12-01 00:00:00

abstract：AIM:To estimate the direct and indirect costs of morbidity and mortality attributable to alcohol consumption in Germany from a societal perspective in 2002. METHODS:Using the concept of attributable risks and the prevalence-based approach, age- and gender-specific alcohol-attributable fractions for morbidity and morta...

journal_title：PharmacoEconomics

authors： Konnopka A,König HH

更新日期：2007-01-01 00:00:00

abstract：:Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

journal_title：PharmacoEconomics

authors： Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

更新日期：2019-02-01 00:00:00

abstract：INTRODUCTION:This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The...

journal_title：PharmacoEconomics

authors： Kohli M,Attard C,Lam A,Huse D,Cook J,Bourgault C,Alemao E,Yin D,Marentette M

更新日期：2006-01-01 00:00:00

abstract：:This willingness-to-pay (WTP) analysis is the first study of its kind undertaken in Australia to support an application for listing of a new drug on the Australian national formulary. The technique offers the advantage of being able to summarise diverse outcomes of therapy in a single unit of measure. Willingness to p...

journal_title：PharmacoEconomics

authors： Davey P,Grainger D,MacMillan J,Rajan N,Aristides M,Dobson M

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...

journal_title：PharmacoEconomics

authors： Knox SA,Viney RC,Street DJ,Haas MR,Fiebig DG,Weisberg E,Bateson D

更新日期：2012-12-01 00:00:00

abstract：:Studies have not previously reported the indirect cost burden of multiple sclerosis (MS) from an employer perspective. To compare annual indirect costs between privately insured US employees with MS and matched employee controls. A retrospective analysis of a privately insured claims database containing disability dat...

journal_title：PharmacoEconomics

authors： Ivanova JI,Birnbaum HG,Samuels S,Davis M,Phillips AL,Meletiche D

更新日期：2009-01-01 00:00:00

abstract：:It has become increasingly popular to carry out cost-effectiveness analyses in economic evaluations of healthcare programmes. Cost-effectiveness analysis is based on the maximisation of the health effects for a given amount of resources. However, many published studies fail to report the results of cost-effectiveness ...

journal_title：PharmacoEconomics

authors： Karlsson G,Johannesson M

更新日期：1996-02-01 00:00:00

abstract：BACKGROUND:Combination therapies with cetuximab (Erbitux®; Merck Serono UK Ltd) and panitumumab (Vectibix®; Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the rat sarcoma (RAS) family. OBJECTIVE:The objecti...

journal_title：PharmacoEconomics

authors： Tikhonova IA,Huxley N,Snowsill T,Crathorne L,Varley-Campbell J,Napier M,Hoyle M

更新日期：2018-07-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes. DESIGN AND SETTING:A Markov process model was constructed to model the effectiveness, as measured by time without depression, ...

journal_title：PharmacoEconomics

authors： Nuijten M,Hadjadjeba L,Evans C,van den Berg J

更新日期：1998-10-01 00:00:00

abstract：:The objective of this study was to compare the cost effectiveness of amoxicillin/clavulanic acid with other antibacterial regimens for prophylaxis of infection after elective abdominal or gynaecological surgery. Data from 21 previously published comparative clinical trials were used to calculate statistical confidence...

journal_title：PharmacoEconomics

authors： Davey PG,Parker SE,Crombie IK,Jaderberg M

更新日期：1995-04-01 00:00:00

abstract：BACKGROUND:The measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited. OBJECTIVE:The objective of this study was to evaluate the feasibili...

journal_title：PharmacoEconomics

authors： Dalziel K,Catchpool M,García-Lorenzo B,Gorostiza I,Norman R,Rivero-Arias O

更新日期：2020-05-01 00:00:00

abstract：BACKGROUND:Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the...

journal_title：PharmacoEconomics

authors： Parthan A,Leahy KJ,O'Sullivan AK,Iakoubova OA,Bare LA,Devlin JJ,Weinstein MC

更新日期：2013-06-01 00:00:00

abstract：BACKGROUND:Coronary heart disease (CHD) is a public health priority in the UK. The National Service Framework (NSF) has set standards for the prevention, diagnosis and treatment of CHD, which include the use of cholesterol-lowering agents aimed at achieving targets of blood total cholesterol (TC) < 5.0 mmol/L and low d...

journal_title：PharmacoEconomics

authors： Wilson K,Marriott J,Fuller S,Lacey L,Gillen D

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Potential differences in toxicity, potency and acquisition price among the liposomal amphotericin B formulations makes it unclear which agent is less costly when total resource consumption and treatment-associated costs are considered. DESIGN:A retrospective cost-minimisation analysis in 51 patients was per...

journal_title：PharmacoEconomics

authors： Kuti JL,Kotapati S,Williams P,Capitano B,Nightingale CH,Nicolau DP

更新日期：2004-01-01 00:00:00

abstract：INTRODUCTION AND OBJECTIVE:The National Cholesterol Education Program recommends regular physician follow-up and lipid testing to promote adherence with lipid-lowering medications. The objective of this study was to determine whether lipid tests and physician visits after treatment initiation are indeed associated with...

journal_title：PharmacoEconomics

authors： Benner JS,Tierce JC,Ballantyne CM,Prasad C,Bullano MF,Willey VJ,Erbey J,Sugano DS

更新日期：2004-01-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00